Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol.
Fibrinolytic activity in plasma euglobulin fractions can be increased by oral administration of stanozolol. This increase is not caused by increased synthesis or release of tissue-type plasminogen activator. A decreased level of fast acting t-PA inhibition is very probably the cause of the higher activity. These results suggest that this inhibition has a regulatory role on fibrinolysis in vivo.
D000328:Adult; D005342:Fibrinolysis / Q000187:drug effects; D006023:Glycoproteins / Q000502:physiology*; D006801:Humans; D007700:Kinetics; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors*; D015849:Plasminogen Inactivators; D012016:Reference Values; D013197:Stanozolol; D013997:Time Factors
D006023:Glycoproteins; D015849:Plasminogen Inactivators; D013197:Stanozolol; D010960:Plasminogen Activators